Study Comparing Lymphoseek® vs. Albumin Nanocolloid in Head and Neck, Melanoma and Breast Cancer
NCT04261179 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30
Last updated 2020-02-20
Summary
Comparison of the concordance of albumin nanocolloid and Lymphoseek® in the detection of lymph nodes of primary and secondary stage drainage by performing two lymphogammagrams
Conditions
- Head Cancer
- Neck Cancer
- Melanoma
- Breast Cancer
Interventions
- DRUG
-
Lymphoseek
50 μg microgram(s), timepoint: 30-60 minutes
- DRUG
-
Nanocoll
500 μg microgram(s), timepoint: 30-60 minutes
Sponsors & Collaborators
-
Anna Cruceta
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-03-31
- Primary Completion
- 2021-02-28
- Completion
- 2021-08-31
Countries
- Spain
Study Locations
More Related Trials
-
A Phase IB Study Of The BTKi CC-292 Combined With Lenalidomide In Adults Patients With Relapsed/Refractory B-Cell Lymphoma
NCT01766583 ·Status: COMPLETED ·Phase: PHASE1
-
This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma
NCT06427213 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL
NCT06086197 ·Status: RECRUITING ·Phase: PHASE2
-
Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00244985 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma
NCT05618925 ·Status: RECRUITING ·Phase: PHASE1
-
A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL)
NCT04129710 ·Status: RECRUITING ·Phase: PHASE2
-
Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma
NCT06558604 ·Status: RECRUITING ·Phase: PHASE2
-
Identification of Occupational Exposures in Acute Hematologic Malignancy
NCT03316209 ·Status: COMPLETED
-
Primary Mediastinal Large B-cell Lymphoma (PMBCL): Multicenter Retrospective Study
NCT05162170 ·Status: COMPLETED
-
A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma
NCT06656221 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study of LY2835219 in Japanese Participants With Advanced Cancer
NCT02014129 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL
NCT04876092 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase I/II Study of Diffuse Large B-cell Lymphoma
NCT04856137 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
An Ambispective Cohort Study of Orelabrutinib in Combination With Standard Treatment Regimen for Untreated DLBCL
NCT06015464 ·Status: UNKNOWN
-
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
NCT01197560 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Clinico-Pathologic Study of Primary Mediastinal B-Cell Lymphoma
NCT00944567 ·Status: COMPLETED
-
Study to Assess Effectiveness and Safety of Zanubrutinib for Patients With Marginal Zone Lymphoma Treated in Italy Under the Named Patient Program (NPP)
NCT06823960 ·Status: RECRUITING
-
Study of the Clearance of Minimal Residual Disease Measured at the End of First-line Treatment in Patients With Lymphoma
NCT06744075 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)
NCT04809467 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma
NCT06213311 ·Status: RECRUITING ·Phase: PHASE2
-
An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Relapsing or Refractory Chronic Lymphocytic Leukemia
NCT01488162 ·Status: COMPLETED
-
Safety and Early Signs of Efficacy of IL12-L19L19.
NCT04471987 ·Status: RECRUITING ·Phase: PHASE1
-
Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)
NCT02658968 ·Status: COMPLETED ·Phase: PHASE1
-
Observational Retrospective Cohort Study of Systemic Therapies for R/R DLBCL
NCT04697160 ·Status: COMPLETED
-
Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma
NCT02776813 ·Status: COMPLETED ·Phase: PHASE1